“Laupheimer Zelltage” to be held on June 2-3, 2014 in Laupheim, Germany
Laupheim, Germany, March 14, 2014 / B3C newswire / - Virus-based biologics play an increasing role in the development of innovative gene, immuno and virotherapeutics. Novel virus-based carrier technologies such as virus-like particles are breaking into new vaccine sectors. The first approval of a gene therapeutic (Glybera®) in Europe as well as various reports of success from gene therapy trials are bolstering confidence in the potential of gene therapy. Also the development of oncolytic viruses for cancer immunotherapy is attracting more and more attention. Common to all of these virus-based biologics is their high degree of complexity, creating the necessity for high levels of understanding of virus and cell biology as well as a multiplicity of innovative technologies. The manufacturing of virus-based biologics is setting new standards for process development and analytical and regulatory requirements.
Against this background Rentschler invites under the heading Processes for Virus-based Biologics to the third Industrial Cell Culture Technology Conference. The conference will take place on June 2-3, 2014 at Laupheim's historical castle, Schloss Großlaupheim.
With the Industrial Cell Culture Technology Conference “Laupheimer Zelltage” Rentschler has established a unique platform for the international exchange of knowledge, ideas and expertise. Held every two years, it attracts global leaders and forward thinkers in the field of biotechnology. As these experts discuss the application of cutting-edge developments, important breakthroughs emerge in the manufacturing of biologics.
Processes for Virus-based Biologics include all aspects related to platform technologies for the manufacturing and control of viral biopharmaceuticals including viral vectors, oncolytic viruses and virus-based vaccines. The conference will bring together international academic and industrial experts in cell culture and process technology for the production of virus-based biologics and is the first conference of its type eagerly awaited by the scientific and industrial community. The keynote lecture will be held by Florian Wurm (Swiss Federal Institute of Technology). The full program and organization details can be found here: http://rentschler.de/en/information/laupheimer-zelltage/
About Rentschler
Rentschler provides a various portfolio of manufacturing services for biopharmaceuticals. Focused on the utilization of mammalian cell lines, Rentschler’s long experience covers the development and production of recombinant proteins in compliance with international GMP standards. Rentschler’s customized solutions range from supporting drug candidate selection, cell line and process development capabilities as well as GMP production to comprehensive analytics and fill & finish. Rentschler’s state-of-the-art manufacturing facility includes bioreactors up to 3,600 L and aseptic filling lines for vials (including lyophilization) and prefilled syringes. The long-term experience with international regulatory affairs and authorities complements the offerings. Rentschler’s full-service concept allows flexibility on the individual project requirements.
Contact for more information about the conference:
Prof. Dr. Roland Wagner
Senior Vice President Development
Tel.: +49 - 7392 701-857
This email address is being protected from spambots. You need JavaScript enabled to view it.